Sequencing of the 46 Cancer Gene Panel (including the tumor suppressor gene TP53 and proto-oncogenes listed in Supplementary Table 2) in the primary lines, MESO-3T, MESO-7T, MESO-8T, MESO-12T and both commercial cell lines, did not reveal any genetic alterations besides common polymorphisms (data not shown). This evidence concerns the gene TP53 and cancer.